ArticleThe oncologist2017
Complete Metabolic Response on Interim
Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Prognostic value ofBreast cancer research : BCR · 2020Pooled it
- Pooled it
- FDG PET/CT in the post-treatment evaluation of breast cancer: an emphasis on triple-negative breast cancer.American journal of nuclear medicine and molecular imaging · 2026Review
- Prognostic value of molecular and radiologic characteristics on dedicated breast [EJNMMI research · 2025Article
- Changes in Intratumor Blood Flow After Carbon-Ion Radiation Therapy for Early-Stage Breast Cancer.International journal of particle therapy · 2024Article
- Image quality evaluation for a clinical organ-targeted PET camera.Frontiers in oncology · 2024Article
- Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer.Journal of gynecologic oncology · 2022Article
- Article
- The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review.Heart failure reviews · 2021Review
- Article
- Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer.Frontiers in oncology · 2020Review
- Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.Breast cancer research : BCR · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThis study aims to investigate the prognostic role of complete metabolic response (CMR) on interim PATIENTS AND
methodsEighty-six consecutive patients with stage II/III BC who received PET/CT during or following NAC were included. Time-dependent receiver operating characteristic analysis and Kaplan-Meier analysis were used to determine correlation between metabolic parameters and survival outcomes.
resultsThe median follow-up duration was 71 months. Maximum standardized uptake value (SUV
conclusionCMR indicated a significantly better outcome in BC and may serve as a favorable imaging prognosticator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.